Cargando…
Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2
A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagent...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642387/ https://www.ncbi.nlm.nih.gov/pubmed/34862448 http://dx.doi.org/10.1038/s41598-021-02942-4 |
| _version_ | 1784609672062304256 |
|---|---|
| author | Davies, Katherine Arnold, Ulrike Buczkowski, Hubert Burton, Christopher Welch, Stephen R. Green, Nicole Strachan, Rhea Beetar-King, Tracy Spencer, Peter Hettiarachchi, Nipunadi Hannah, Matthew J. Jones, Matthew Cane, Patricia A. Bruce, Christine B. Woodford, Neil Roberts, Allen D. G. Killip, Marian J. |
| author_facet | Davies, Katherine Arnold, Ulrike Buczkowski, Hubert Burton, Christopher Welch, Stephen R. Green, Nicole Strachan, Rhea Beetar-King, Tracy Spencer, Peter Hettiarachchi, Nipunadi Hannah, Matthew J. Jones, Matthew Cane, Patricia A. Bruce, Christine B. Woodford, Neil Roberts, Allen D. G. Killip, Marian J. |
| author_sort | Davies, Katherine |
| collection | PubMed |
| description | A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures. |
| format | Online Article Text |
| id | pubmed-8642387 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86423872021-12-06 Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 Davies, Katherine Arnold, Ulrike Buczkowski, Hubert Burton, Christopher Welch, Stephen R. Green, Nicole Strachan, Rhea Beetar-King, Tracy Spencer, Peter Hettiarachchi, Nipunadi Hannah, Matthew J. Jones, Matthew Cane, Patricia A. Bruce, Christine B. Woodford, Neil Roberts, Allen D. G. Killip, Marian J. Sci Rep Article A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures. Nature Publishing Group UK 2021-12-03 /pmc/articles/PMC8642387/ /pubmed/34862448 http://dx.doi.org/10.1038/s41598-021-02942-4 Text en © Crown 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Davies, Katherine Arnold, Ulrike Buczkowski, Hubert Burton, Christopher Welch, Stephen R. Green, Nicole Strachan, Rhea Beetar-King, Tracy Spencer, Peter Hettiarachchi, Nipunadi Hannah, Matthew J. Jones, Matthew Cane, Patricia A. Bruce, Christine B. Woodford, Neil Roberts, Allen D. G. Killip, Marian J. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title | Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title_full | Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title_fullStr | Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title_full_unstemmed | Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title_short | Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2 |
| title_sort | virucidal efficacy of guanidine-free inactivants and rapid test buffers against sars-cov-2 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642387/ https://www.ncbi.nlm.nih.gov/pubmed/34862448 http://dx.doi.org/10.1038/s41598-021-02942-4 |
| work_keys_str_mv | AT davieskatherine virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT arnoldulrike virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT buczkowskihubert virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT burtonchristopher virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT welchstephenr virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT greennicole virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT strachanrhea virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT beetarkingtracy virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT spencerpeter virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT hettiarachchinipunadi virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT hannahmatthewj virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT jonesmatthew virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT canepatriciaa virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT brucechristineb virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT woodfordneil virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT robertsallendg virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 AT killipmarianj virucidalefficacyofguanidinefreeinactivantsandrapidtestbuffersagainstsarscov2 |